4888.T
STELLA PHARMA CORPORATION
グロース · 医薬品 · 医薬品 · JP
JPY 358.00
+0.85%Year over year
Reported trailing growth
- Revenue
- -66.4%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +16.7%
- EBITDA
- —
- EPS
- -16.9%
Three-year CAGR
- Revenue
- +12.1%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026